TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02239679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aminolevulinic Acid
Description: 20% ALA applied to face for one hour prior to 10 J/cm2 blue light

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aminolevulinic Acid
Description: 20% ALA applied to face for one hour prior to 10 J/cm2 blue light

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topical Solution Vehicle
Description: Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to face one hour prior to 10 J/cm2 blue light

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BLU-U
Description: 10 J/cm2 blue light delivered at 10 mW/cm2

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BLU-U
Description: 10 J/cm2 blue light delivered at 10 mW/cm2
Study: NCT02604147

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Inspiratory pressure-threshold muscle training device.
Description: The participants who will be allocated in this simulated intervention group will have to do a simulated inspiratory muscle training protocol through the inspiratory muscle exerciser POWERbreathe, model Sports Plus Heavy Resistance (POWERbreathe; HAB International Ltd., Warwickshire, United Kingdom) for 12 weeks five times at week and twice daily, with a load of 15% of maximal inspiratory pressure without progression. In each session will be requested to the volunteers make 30 slow breaths, which will be constantly supervised by the researchers.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nspiratory pressure-threshold muscle training device.
Description: The participants who will be allocated in this intervention group will have to make a inspiratory muscle training protocol with progressive loads through the inspiratory muscle exerciser POWERbreathe, model Sports Plus Heavy Resistance (POWERbreathe; HAB International Ltd., Warwickshire, United Kingdom) for 12 weeks five times at week and twice daily, with an initial load of 50% of maximal inspiratory pressure, progressing to 60% after the fourth week, and 70% after the octave week. In each session will be requested to volunteers who performed 30 maximal and prolonged inspiration, maintaining the diaphragmatic breathing, which will be constantly supervised by the researchers.
Study: NCT03022734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy
Description: cetuximab 250mg/m2 or bevacizumab 5mg/kg, FOLFOX (oxaliplatin 85mg/m2, leucovorin 200mg/m2, 5-FU 400mg/m2, 5-FU continuous 1200mg/m2) or FOLFIRI (irinotecan 180mg/m2, leucovorin 200mg/m2, 5-FU 400mg/m2, 5-FU continuous 1200mg/m2)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: After FOLFOX 4cycle, subject have short course radiotherapy 5Gy for 5 days.
Study: NCT03517371

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mHealth delivered exercise program
Description: Participants in the mobile health condition have up to 10 in-person visits with a physical therapist over 12 months. The exercise program, consisting of walking, strengthening and stretching exercises, is prescribed through an app and remotely adapted by a physical therapist over 1 year. Approximately 5-7 exercises are implemented 5 days per week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise only
Description: Participants in the control group have up to 10 in-person visits with the intervention physical therapist over 12-months. Participants are instructed by the physical therapist to engage in walking and perform progressive resistance and stretching exercises (tailored to their needs and provided in written format) 5 days per week.
Study: NCT01468025

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Theramine and Active Naproxen
Description: Co-administration of Theramine and Naproxen, CoPack Kit Theraproxen

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Theramine and naproxen-like placebo
Description: Theramine, a medical food, co-administered with naproxen-like placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen and Theramine-like placebo
Description: naproxen co-administered with Theramine-like placebo.
Study: NCT02409823

Intervention type: DRUG
Intervention: Atypical Antipsychotics
Description: any atypical antipsychotic
Study: NCT00957671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone
Description: 200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total)
Study: NCT04388514

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Medical Ozone procedure
Description: The systemic ozone treatment procedure was decided by the physician on duty and started preliminarily at the patient's bed with the drawing of autologous blood and, after proper O2/O3 mixing, with its re-infusion. After junction of an adequate venous patient's way with a dedicated latex free plastic bag containing 35 ml of sodium citrate, a blood amount of 200 ml is taken. At the end, the withdrawal line was washed and the re-infusion one was filled with saline solution. The blood, without any patient disconnection, was then mixed with a gas mixture of a 200 cc composed by 96% of Oxygen and 4% of Ozone with a therapeutic O3 range of 40 μg/mL of gas per mL of blood. In order to guarantee the O2/O3 homogeneous diffusion into the blood, the bag was gently mixed for about 10 minutes, therefore the blood was re-infused into the patients. The duration of ozone treatment lasted for 3 consecutive days.
Study: NCT02158793

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Craniomaxillofacial allotransplantation
Description: Transplantation of donor face
Study: NCT03999697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autologous chimeric antigen receptor T cell transfusing agent targeting CD22
Description: The enrolled patients will receive autologous-derived CD22-targeted CAR-T cells in 1 day with 100% of the total expected dosage after receiving lymphodepleting chemotherapy
Study: NCT01225705

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: raltegravir
Description: Patients will be randomized 1:1 to either the experimental or the active control arm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atazanavir/ritonavir
Description: Patients will be randomized 1:1 to either the experimental or the active control arm
Study: NCT00850798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intensive glycemic control
Description: Intensive glycemic control

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conservative glycemic control
Description: OADs and insulin
Study: NCT02286427

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Amniotic Membrane

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Amniotic Membrane
Study: NCT02896218

Intervention type: OTHER
Intervention: Pharmacists consultation
Description: Pharmacists consultation of vancomycin individualized dosing strategy
Study: NCT02744898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin AUC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane
Description: 100mg/m2
Study: NCT02574949

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation: 15 FPS Cine 15 PPS
Description: Radiation 15 FPS Cine 15 PPS

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation: 7.5 low Frame rate
Description: Radiation: Frame rate 7.5 FPS, Cine 15 PPS

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low Cine
Description: Radiation: Frame rate 7.5 FPS, Cine 10 PPS
Study: NCT02113150

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: remifentanil
Description: renal function

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: renal function
Study: NCT01504919

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Education
Description: Brief counseling at baseline, at 6 months and again at 12 months, and self-help materials addressing smoking cessation, diet, physical activity, referrals to available resources, and a home-based exercise kit (e.g., pedometer, exercise ball, strength training cables).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Education
Description: Brief counseling at baseline, at 6 months and again at 12 months, and self-help materials addressing smoking cessation, diet, physical activity, referrals to available resources, and a home-based exercise kit (e.g., pedometer, exercise ball, strength training cables).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Computer-based questionnaires completed at baseline, then every 6 months taking 60-90 minutes to complete.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Computer-based questionnaires completed at baseline, then every 6 months taking 60-90 minutes to complete.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone Counseling Sessions
Description: 9 proactive, telephone counseling sessions over 18 months. Each of these phone calls should last about 20-30 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Patches
Description: 6-week supply of nicotine patches given to participants ready to quit smoking.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Patches
Description: 6-week supply of nicotine patches given to participants ready to quit smoking.
Study: NCT04034914

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire administration
Description: Ancillary studies
Study: NCT03895892

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 20 km time trial
Description: 20 km time trial cycling test will be conducted to measure the effect of different drinks on time

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 20 km time trial
Description: 20 km time trial cycling test will be conducted to measure the effect of different drinks on time

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: 20 km time trial
Description: 20 km time trial cycling test will be conducted to measure the effect of different drinks on time

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wingate test
Description: 30 second all-out effort on a bike will be conducted to measure the effect of different drinks on peak power output

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wingate test
Description: 30 second all-out effort on a bike will be conducted to measure the effect of different drinks on peak power output
Study: NCT02239679

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: BLU-U
Description: 10 J/cm2 blue light delivered at 10 mW/cm2

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Description: Liquid nitrogen cryotherapy by standard of care method to all visible/palpable actinic keratosis (AK) lesions at screening.
Study: NCT03895892

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Wingate test
Description: 30 second all-out effort on a bike will be conducted to measure the effect of different drinks on peak power output

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketone/Caffeine
Description: Dietary supplement containing ketone salts and caffeine

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketone
Description: Dietary supplement containing only ketone salts

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Water Placebo
Description: Dietary supplement containing only water
Study: NCT04611724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX
Description: oxaliplatin 85 mg/m2 IV over 2 hours leucovorin 400 mg/m2 over 2 hours irinotecan 150 mg/m2 over 90 min, 5-FU continuous infusion 2400 mg/m2 continuous infusion over 46 hours
Study: NCT01439997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desmopressin
Description: Administration of minirin melt 60 µg: desmopressin (acetate) 60 µg oral lyophilisate.
Study: NCT00724750

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gauze suction (G-SUC)
Description: Negative pressure wound therapy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vacuum Assisted Closure Device (VAC)
Description: Negative Pressure Wound Therapy
Study: NCT02239679

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Description: Liquid nitrogen cryotherapy by standard of care method to all visible/palpable actinic keratosis (AK) lesions at screening.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Cryotherapy
Description: Liquid nitrogen cryotherapy by standard of care method to all visible/palpable actinic keratosis (AK) lesions at screening.
Study: NCT03387592

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CPT-11
Description: 180 mg/m2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcio levofolinate
Description: 200 mg/m2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Fluorouracil
Description: 400 mg/m2 + 2400 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1500 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: 200 mg/m2
Study: NCT04301843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eflornithine
Description: DFMO (difluoromethylornithine) will be given at a dose of 1000 mg/m2 BID on each day of study.
Study: NCT02701595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: amoxicillin 1500 mg x3/day (for patients ≤70kg) or 2000 mg x3/day (for patients \>70kg)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional IV treatment of streptococci/enterococci IE following European guidelines 2015 including amoxicillin, gentamicin, amicillin, vancomycin, penicillin G, ceftriaxone, netilmicin
Description: Conventional IV treatment of streptococci/enterococci IE following European guidelines 2015 including amoxicillin, gentamicin, amicillin, vancomycin, penicillin G, ceftriaxone, netilmicin
Study: NCT01446042

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone
Description: Intranasal testosterone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone
Description: Intranasal testosterone
Study: NCT03999398

Intervention type: PROCEDURE
Intervention: Percutaneous coronary intervention (PCI)
Description: Participants are treated with a PCI and stent implantation in a venous graft (previously implanted during the CABG operation)

Intervention type: PROCEDURE
Intervention: Percutaneous coronary intervention (PCI)
Description: Participants are treated with a PCI and stent implantation in a venous graft (previously implanted during the CABG operation)
Study: NCT04647851

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remote exercise intervention Down syndrome
Description: See arm description
Study: NCT00216619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate - Placebo
Description: the trial medication consisted of topiramate 25 mg tablets or matching placebo tablets which were identical in appearance, taste and smell. DB randomisation phase (after the 26-weeks OL phase) were randomly allocated (1:1) to one of the two treatment groups (topiramate or placebo). The randomisation took place at Visit 6 (Week 26)
Study: NCT02724553

Intervention type: DEVICE
Group type: OTHER
Intervention: Acrylic lens implantation

Intervention type: DEVICE
Group type: OTHER
Intervention: Acrylic lens implantation
Study: NCT00228020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: basiliximab, MMF(mycophenolate mofetil), cyclosporine, prednisone (or equivalent)
Study: NCT00412802

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dose adaptation of Enoxaparin
Description: A same initial dose of 1 mg/kg will be administrated to all patients. According to creatinine clearance, the next doses (every 12 hours subcutaneously) will be adjusted with a 25% dose reduction if creatinine clearance is comprised between 30 and 50 ml/min.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: normal injection of Enoxaparine
Description: No dose adaptation of Enoxaparine
Study: NCT00843245

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT01252433

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Energy density feeding study
Description: In a crossover study, children are served all foods 1 day a week for 3 weeks. Meal entrees will vary in energy density (100%, 85%, 75%).
Study: NCT03100578

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WOPN TRANSMURAL DRAINAGE: PLASTIC STENT
Description: Endoscopic ultrasound-guided transmural drainage of walled-off pancreatic necrosis:~The pancreatic collection will be located with the linear echoendoscope, and we will proceed to choose an optimal area to perform the puncture guided by EUS; with the absence of intervening vessels.~This collection will be punctured with a 19 G needle or with an electrocautery device directly. Guidance will be advanced through the needle and the ostomy will proceed according to the routine of the experienced endoscopist.~Placement of a plastic double pigtail, 5-10 cm in length, diameters 7-8,5-10 Fr. Minimum one 10 Fr prosthesis.~Arm associated: PLASTIC STENT

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: WOPN TRANSMURAL DRAINAGE: METALLIC STENT
Description: Endoscopic ultrasound-guided transmural drainage of walled-off pancreatic necrosis:~The pancreatic collection will be located with the linear echoendoscope, and we will proceed to choose an optimal area to perform the puncture guided by EUS; with the absence of intervening vessels.~This collection will be punctured with a 19 G needle or with an electrocautery device directly. Guidance will be advanced through the needle and the ostomy will proceed according to the routine of the experienced endoscopist.~Placement of a metal self-expanding fully covered luminal apposition stent: 10, 15 or 20 mm diameter.~Arm associated: SELF EXPANDABLE METALLIC STENT
Study: NCT02815904

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yakson touch
Description: Yakson is a Korean therapeutic touch given to neonates and infants by caressing their abdomen with one hand while the other hand is placed on the back of the neonate\\infant to relieve their pain or to calm them down.
Study: NCT02045745

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Implantation of autologous mesenchymal stem cells (CSM) expanded in vitro and administered directly into the lung suture line
Description: Patients at risk of prolonged postoperative air leak will be treated by local administration of autologous mesenchymal cells expanded in vitro
Study: NCT01073774

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Side by side

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: couples control condition
Study: NCT03158519

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iMETX intervention
Description: Pre-intervention the participants will wear the running watch for 3 weeks so that researchers can collect data about their daily routines regarding where and how much energy they expend.~During the intervention participants will wear the running watch for 12 weeks. Every 1-3 days the participants will be given an individualized recommendation for how to increase their activity via the iMETX application. Participants will be able to provide feedback to the researchers throughout intervention period regarding what works and does not in terms of the recommendations for increasing activity.~Post-intervention the participants will wear the running watch for 12 weeks so that researchers can collect data in order to determine whether physical activity changes made during the intervention are sustained.
Study: NCT02467790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEX168
Description: PEX 168: 200µg,Subcutaneous,one time.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEX168
Description: PEX 168: 200µg,Subcutaneous,one time.
Study: NCT03684434

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online MI plus Online CBT
Description: An online motivational interviewing (MI) lesson will first be delivered to clients. The MI lesson is expected to take one hour to complete. No therapist support will be provided during this component of treatment. An 8-week Internet-delivered cognitive behavioural therapy (ICBT) will be then delivered to clients following completion of online MI. Clients will receive weekly support in the form of emails and phone calls from registered social workers, psychologists or supervised graduate students, who have experience delivering ICBT. Therapist will spend approximately 15 minutes per week/per client.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online CBT
Description: An 8-week Internet-delivered cognitive behavioural therapy (ICBT) will be delivered to clients. Clients will receive weekly support in the form of emails and phone calls from registered social workers, psychologists or supervised graduate students, who have experience delivering ICBT. Therapist will spend approximately 15 minutes per week/per client.
Study: NCT01391533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR125844
Description: Pharmaceutical form:solution~Route of administration: intravenous
Study: NCT01825018

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Network Leader Endorsement
Description: Leaders of the 16 intervention condition networks will attend a 7-session intervention, with the first 5 sessions held weekly and the last 2 at biweekly intervals. Networks will include persons with differing care histories including PLH never in care, those who dropped out of care, and those who attend medical appointments irregularly or are inconsistent in adherence. Network leaders will be trained to tailor communications to each friend's care circumstances. Issues of current injecting drug users (IDUs) may differ from non-IDUs. Therefore, intervention content will be tailored based on formative phase findings, and groups for IDU network leaders will be held separately.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HIV Counseling
Description: At the baseline session, participants in the comparison condition will receive counseling about the benefits and availability of HIV care and the importance of treatment adherence.